Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidates Potential in DNA Age Reversal Science
| TELO Stock | 4.91 0.03 0.61% |
About 61% of Telomir Pharmaceuticals,'s investor base is looking to short. The analysis of overall sentiment of trading Telomir Pharmaceuticals, Common stock suggests that many investors are alarmed at this time. Telomir Pharmaceuticals,'s investing sentiment overview a quick insight into current market opportunities from investing in Telomir Pharmaceuticals, Common. Many technical investors use Telomir Pharmaceuticals, stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Telomir |
Continued work with computer-aided pre-clinical testing shows Telomir-1 has the potential to extend DNA telomeres to reverse age-related conditionsBALTIMORE, March 14, 2024 -- Telomir Pharmaceuticals, Inc. , a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNAs protective telomere caps in order to potentially reverse age-related co
Read at finance.yahoo.com
 |
Telomir Pharmaceuticals, Fundamental Analysis
We analyze Telomir Pharmaceuticals,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Telomir Pharmaceuticals, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Telomir Pharmaceuticals, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
Telomir Pharmaceuticals, is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Telomir Pharmaceuticals, Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Telomir Pharmaceuticals, stock to make a market-neutral strategy. Peer analysis of Telomir Pharmaceuticals, could also be used in its relative valuation, which is a method of valuing Telomir Pharmaceuticals, by comparing valuation metrics with similar companies.
Peers
Telomir Pharmaceuticals, Related Equities
| EBS | Emergent Biosolutions | 4.60 | ||||
| NBIX | Neurocrine Biosciences | 2.74 | ||||
| ALVO | Alvotech | 2.12 | ||||
| HLN | Haleon Plc | 1.95 | ||||
| TEVA | Teva Pharma | 0.06 |
Check out Telomir Pharmaceuticals, Hype Analysis, Telomir Pharmaceuticals, Correlation and Telomir Pharmaceuticals, Performance. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Telomir Pharmaceuticals,. If investors know Telomir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Telomir Pharmaceuticals, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.78) | Return On Assets (2.05) | Return On Equity (17.53) |
The market value of Telomir Pharmaceuticals, is measured differently than its book value, which is the value of Telomir that is recorded on the company's balance sheet. Investors also form their own opinion of Telomir Pharmaceuticals,'s value that differs from its market value or its book value, called intrinsic value, which is Telomir Pharmaceuticals,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Telomir Pharmaceuticals,'s market value can be influenced by many factors that don't directly affect Telomir Pharmaceuticals,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Telomir Pharmaceuticals,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Telomir Pharmaceuticals, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Telomir Pharmaceuticals,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.